NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis $2.36 +0.03 (+1.29%) Closing price 08/7/2026 03:59 PM EasternExtended Trading$2.35 -0.01 (-0.42%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Aytu BioPharma Stock (NASDAQ:AYTU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aytu BioPharma alerts:Sign Up Key Stats Today's Range$2.29▼$2.3650-Day Range$2.06▼$2.3652-Week Range$1.65▼$3.07Volume38,139 shsAverage Volume24,615 shsMarket Capitalization$25.32 millionP/E RatioN/ADividend YieldN/APrice Target$10.75Consensus RatingHold Company Overview Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics. Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States. Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.AI Generated. May Contain Errors. Read More Aytu BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreAYTU MarketRank™: Aytu BioPharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 690th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAytu BioPharma has a consensus price target of $10.75, representing about 355.5% upside from its current price of $2.36.Amount of Analyst CoverageAytu BioPharma has only been the subject of 3 research reports in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aytu BioPharma are expected to grow in the coming year, from ($0.73) to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aytu BioPharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.40% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 15.78, which indicates bearish sentiment.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 0.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.90% of the stock of Aytu BioPharma is held by insiders.Percentage Held by Institutions33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AYTU Stock News HeadlinesAytu BioPharma (NASDAQ:AYTU) Shares Cross Below 50 Day Moving Average - What's Next?July 29, 2026 | americanbankingnews.comAytu BioPharma, Inc.: Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026May 18, 2026 | finanznachrichten.deTrump is bulldozing nuclear's 50-year blockadeFour advanced test reactors just reached criticality, according to the Department of Energy, a milestone that moves compact reactor technology from computer models into physical testing. DOE says follow-on reactors could begin producing electricity as soon as 2027, shifting the industry's focus from whether the technology works to who builds, fuels, and operates it. | Monument Traders Alliance (Ad)Aytu BioPharma, Inc. Q3 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comFull Transcript: Aytu BioPharma Q3 2026 Earnings CallMay 14, 2026 | uk.finance.yahoo.comAytu (AYTU) Q3 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comAytu outlines $6M-$7M quarterly sales and marketing spend range as EXXUA scripts rise to over 920 in AprilMay 14, 2026 | seekingalpha.comAytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...May 14, 2026 | finance.yahoo.comSee More Headlines AYTU Stock Analysis - Frequently Asked Questions How have AYTU shares performed this year? Aytu BioPharma's stock was trading at $2.60 at the start of the year. Since then, AYTU stock has decreased by 9.2% and is now trading at $2.36. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma Inc. (NASDAQ:AYTU) released its earnings results on Wednesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.09. The firm earned $12.41 million during the quarter, compared to analyst estimates of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative trailing twelve-month return on equity of 69.93%. Read the conference call transcript. When did Aytu BioPharma's stock split? Shares of Aytu BioPharma reverse split before market open on Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Aytu BioPharma's major shareholders? Top institutional investors of Aytu BioPharma include Crown Advisors Management Inc. (1.86%), Persistent Asset Partners Ltd (0.35%) and BlackRock Inc. (0.21%). View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE). Company Calendar Last Earnings5/13/2026Today8/08/2026Next Earnings (Estimated)9/29/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 9 days, AYTU's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AYTU CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Aytu BioPharma$10.75 High Price Target$14.50 Low Price Target$7.00 Potential Upside/Downside+355.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.56 million Net Margins-60.17% Pretax Margin-59.49% Return on Equity-69.93% Return on Assets-13.25% Debt Debt-to-Equity Ratio0.27 Current Ratio1.12 Quick Ratio1.00 Sales & Book Value Annual Sales$66.38 million Price / Sales0.38 Cash Flow$0.38 per share Price / Cash Flow6.21 Book Value$2.11 per share Price / Book1.12Miscellaneous Outstanding Shares10,730,000Free Float10,207,000Market Cap$25.32 million OptionableNot Optionable Beta0.25 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AYTU) was last updated on 8/8/2026 by MarketBeat.com Staff. From Our PartnersTrump is bulldozing nuclear's 50-year blockadeFour advanced test reactors just reached criticality, according to the Department of Energy, a milestone that ...Monument Traders Alliance | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
